Meeting Details
The 22nd Annual General Meeting will be held on Saturday, 29th August, 2026 at 4:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025.
Ordinary Business Items
Item No. 01 - Adoption of Audited Financial Statements
To receive, consider and adopt the Standalone Audited Balance Sheet for the year ended 31st March, 2026, the Profit and Loss account for the year ended as on the said date, Cash Flow Statement, Auditors' Report and the Directors' Report thereon.
Item No. 02 - Declaration of Dividend on Preference Shares
To declare dividend on preference shares for the financial year 2025-26.
Item No. 03 - Re-appointment of a Director
To re-appoint Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686) who retires by rotation and being eligible, offers himself for re-appointment as Executive Director of the Company whose office shall be liable to retirement by rotation.
Special Business Items
Item No. 04 - Approval of related party transactions with Activista Healthcare Private Limited
Ordinary resolution to approve existing and new material related party transactions with Activista Healthcare Private Limited, Indore, which is an enterprise over which relatives of KMP are able to exercise significant influence.
Explanatory Statement Details:
- Nature of relationship: Mr. Swapan Khandelwal (Whole Time Director) is a Director of Activista Healthcare
- Type of transactions: Sale of Goods
- Past transactions: FY 25-26: ₹113.00 lakhs, FY 24-25: ₹245.88 Lakhs, FY 23-24: ₹392.68 Lakhs
- Transactions are in ordinary course of business on arm's length basis
- Justification: Acts as distributors/marketing partners for wider market reach
Item No. 05 - Approval of related party transactions with Nucleage Pharma Solutions Private Limited
Ordinary resolution to approve existing and new material related party transactions with Nucleage Pharma Solutions Private Limited, Indore.
Explanatory Statement Details:
- Nature of relationship: Mr. Swapan Khandelwal is a Director of Nucleage Pharma Solutions
- Type of transactions: Sale of Goods
- Past transactions: FY 25-26: ₹555.64 Lakhs, FY 24-25: ₹256.23 Lakhs, FY 23-24: ₹122.68 Lakhs
- Transactions are in ordinary course of business on arm's length basis
- Justification: Acts as distributors/marketing partners for wider market reach
Item No. 06 - Approval of related party transactions with Numerius Healthcare Private Limited
Ordinary resolution to approve existing and new material related party transactions with Numerius Healthcare Private Limited, Indore.
Explanatory Statement Details:
- Nature of relationship: Mr. Swapan Khandelwal is a Director of Numerius Healthcare
- Type of transactions: Sale of Goods
- Past transactions: FY 25-26: ₹1.96 Lakhs, FY 24-25: ₹304.33 Lakhs, FY 23-24: ₹60.75 Lakhs
- Transactions are in ordinary course of business on arm's length basis
- Justification: Acts as distributors/marketing partners for wider market reach
Item No. 07 - Borrowing of Unsecured Loan from directors with Convertibility Option
Special resolution to borrow unsecured loan from Directors subject to overall limit of ₹200 Crores as sanctioned under Section 180(1)(c) of Companies Act, 2013, with conversion right into equity shares.
Terms and Conditions:
- Conversion may be exercised by Directors during loan continuation
- Conversion price to be determined per SEBI regulations at time of conversion
- Converted shares will rank pari passu with existing equity shares
- Company will list converted shares on stock exchanges at its cost
- Conversion notice will trigger allotment of fully paid-up equity shares
- Converted portion ceases to carry interest from conversion date
Item No. 08 - Approval of loans, investments, guarantee or security u/s 185
Special resolution to authorize Board to advance loans, give guarantees, or provide security up to ₹200 Crores to subsidiaries, associates, joint ventures, or Managing Director/Whole Time Director for principal business activities.
Director Re-appointment Details
Mr. Prashant Shrikrishna Karkare (DIN: 06572686), Executive Director:
- Date of birth: 26/03/1966 (60 Years)
- Date of appointment: July 16, 2013
- Qualifications: B.Sc.
- Experience: Over 30 years in pharmaceutical industry
- Previous positions: Kappac Pharma Limited, Paraan Limited, Cipla Limited
- Current shareholding: 27,003 equity shares
- Board meetings attended in FY 2025-26: 9 out of 9
- Past remuneration: ₹11.78 Lakhs
Voting Arrangements
- Remote e-voting period: Tuesday 25th August, 2026 9:00 AM to Friday, 28th August, 2026 5:00 PM
- Cut-off date: Saturday, 22nd August, 2026
- E-voting service provider: Bigshare Services Private Limited
- Scrutinizer: M/s Avinash Gandhewar & Associates, Practicing Company Secretaries, Nagpur
- Physical voting available at meeting venue for those not voting remotely
Document Distribution
Notice and Annual Report sent electronically per SEBI Circular dated January 5, 2023, available on company website www.goldlinepharma.in and BSE website https://www.bseindia.com/